Cargando…

Novel immunotherapies in multiple myeloma – chances and challenges

In this review article, we summarize the latest data on antibody-drug conjugates, bispecific T-cell-engaging antibodies, and chimeric antigen receptor T cells in the treatment of multiple myeloma. We discuss the pivotal questions to be addressed as these new immunotherapies become standard agents in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rasche, Leo, Wäsch, Ralph, Munder, Markus, Goldschmidt, Hartmut, Raab, Marc S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485654/ https://www.ncbi.nlm.nih.gov/pubmed/34196164 http://dx.doi.org/10.3324/haematol.2020.266858

Ejemplares similares

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma
por: Rasche, Leo, et al.
Publicado: (2019)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice
por: Zhou, Xiang, et al.
Publicado: (2022)

Cell-based immunotherapy approaches for multiple myeloma
por: Kriegsmann, Katharina, et al.
Publicado: (2018)

Proteasome inhibition: the dawn of novel therapies in multiple myeloma
por: Engelhardt, Monika, et al.
Publicado: (2022)

Allogeneic Stem Cell Transplantation in Multiple Myeloma
por: Greil, Christine, et al.
Publicado: (2021)

Immunotherapy of Multiple Myeloma: Promise and Challenges
por: Abramson, Hanley N
Publicado: (2021)

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
por: Gay, Francesca, et al.
Publicado: (2018)

IgE-based immunotherapy of cancer: challenges and chances
por: Singer, J, et al.
Publicado: (2014)

Development of Novel Immunotherapies for Multiple Myeloma
por: Al-Hujaily, Ensaf M., et al.
Publicado: (2016)

Selective elimination of immunosuppressive T cells in patients with multiple myeloma
por: Awwad, Mohamed H. S., et al.
Publicado: (2021)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023)

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
por: Kriegsmann, Katharina, et al.
Publicado: (2020)

Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma
por: Sachpekidis, Christos, et al.
Publicado: (2019)

Immunotherapy for Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2019)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
por: Kriegsmann, Katharina, et al.
Publicado: (2019)

The prognostic significance of [(18)F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions
por: Yan, Zhi-Ling, et al.
Publicado: (2022)

The Role of Immunotherapy in Multiple Myeloma
por: Kocoglu, Mehmet, et al.
Publicado: (2016)

Cellular immunotherapy in multiple myeloma
por: Vo, Manh-Cuong, et al.
Publicado: (2019)

Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
por: Goldschmidt, Hartmut, et al.
Publicado: (2018)

A systematic classification of death causes in multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2018)

Can (18)F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?
por: Sachpekidis, Christos, et al.
Publicado: (2020)

Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma
por: John, Lukas, et al.
Publicado: (2023)

Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma
por: Castella, Maria, et al.
Publicado: (2018)

Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2023)

Pathway-Directed Therapy in Multiple Myeloma
por: John, Lukas, et al.
Publicado: (2021)

Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions
por: Verheye, Emma, et al.
Publicado: (2022)

Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology—Highlights of the 8th Heidelberg Myeloma Workshop
por: Lutz, Raphael, et al.
Publicado: (2021)

Immunotherapy Strategies Against Multiple Myeloma
por: Ma, Jing, et al.
Publicado: (2017)

BCMA-targeted immunotherapy for multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

Is immunotherapy here to stay in multiple myeloma?
por: Rodríguez-Otero, Paula, et al.
Publicado: (2017)

Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany
por: Engelhardt, Monika, et al.
Publicado: (2020)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
por: Danylesko, Ivetta, et al.
Publicado: (2012)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
por: Ackley, James, et al.
Publicado: (2021)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Immune checkpoint inhibitors for multiple myeloma immunotherapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dup1sidsr8gq4vfeuvvag6rovd